Abstract
This issue of AJO presents a systematic review by Tang and authors1 focused on a recently-available technology employing twice-daily application of low-intensity red light totalling 6 minutes per day. Initially designed to treat amblyopia, with results that were not encouraging, this intervention now appears effective in reducing myopia progression as measured by refractive power, axial length and visual acuity. The wavelength of light emitted by this machine falls within the visible spectrum, and the source is categorised as Class I, that is safe for direct ocular exposure, according to a widely-used standard.2 Expectations for safety in treatment of a relatively benign condition such as myopia are appropriately high, and more data from larger and longer studies will be needed to exclude or quantify the possibility of rare but serious side effects during home use.3 Nonetheless, it is biologically plausible that this treatment is safe. Given its simple design, it is reasonable to hope that costs may eventually be low. Additional research is needed to clarify the amplitude and clinical implications of “rebound” myopia progression after cessation of treatment, compare efficacy and potential synergy with other treatments, and to better understand the mechanism of action, which may involve reduction of effective axial length through choroidal thickening.
Original language | English |
---|---|
Pages (from-to) | A1-A3 |
Number of pages | 3 |
Journal | American Journal of Ophthalmology |
Volume | 254 |
Early online date | 22 Sept 2023 |
DOIs | |
Publication status | Published - Oct 2023 |